Table. 1. Table 1

Characteristics of studies included in the meta-analysis

Study	Country	Design	SARS-COV-2 variant	Transplant type	No. of patients	No. of male	Intervention	Control	COVID-19 severity	COVID-19 vaccination rate (%)
Casutt et al. (2023) [15]	Switzerland	RS	Delta, Omicron	Lung	60	31	SOT	C/I, T/C	Mild or moderate	72^a)
Chavarot et al. (2022) [8]	France	RS	Omicron	Kidney	125	75	SOT	SOC	Mild or moderate	SOT, 96; SOC, 96.2
Fernandes et al. (2022) [16]	Belgium	RS	Omicron, Delta	Kidney	47	26	SOT	C/I	Mild or moderate	SOT, 84; C/I, 81
Gleeson et al. (2022) [17]	United Kingdom	RS	Omicron	Kidney	116	63	SOT	SOC, MOL	NR	SOT, 87; SOC, 81; MOL, 100
Hedvat et al. (2022) [4]	United States	RS	Omicron	Heart, kidney, liver, pancreas, lung	154	NR	SOT	SOC, N/R	Mild or moderate	SOT, 84.3; SOC, 81; N/R: 85.8
Papadimitriou-Olivgeris et al. (2022) [18]	Switzerland	RS	Omicron	Kidney	243	157	SOT	CI	NR	37^a)
Radcliffe et al. (2022) [10]	United States	RS	Omicron	Heart, kidney, liver, pancreas	122	70	SOT	MOL, N/R, SOC	Mild or moderate	SOT, 88; SOC, 81; MOL, 92; N/R, 100
Solera et al. (2022) [11]	Canada	RS	Omicron	Heart, kidney, liver, pancreas, lung	300	171	SOT	SOC	NR	63.6^a)
Wong et al. (2022) [19]	Australia	RS	Omicron	Kidney, pancreas	41	21	SOT	SOC	NR	97.6^a)
Yetmar et al. (2022) [9]	United States	RS	Omicron	Heart, kidney, liver, pancreas, lung	361	229	SOT	BEB	Mild or moderate	SOT, 87; BEB, 85.9

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; RS, retrospective study; SOT, sotrovimab; C/I, casirivimab/imdevimab; T/C, tixagevimab/cilgavimab; SOC, standard of care; MOL, molnupiravir; NR, not reported; N/R, nirmatrelvir/ritonavir; BEB, bebtelovimab.

^a)Total COVID-19 vaccination rate.

Korean J Transplant 2023;37:277~285 https://doi.org/10.4285/kjt.23.0038